NextBio Announces Translational Medicine Partnership with Sanofi
News May 02, 2013
NextBio has announced a multi-year collaboration with Sanofi aimed at using NextBio Clinical to incorporate patient omics and clinical data into Sanofi's drug research and development, as part of Sanofi's Translational Medicine for Patients (TM4P) program.
NextBio will provide Sanofi with the NextBio Clinical platform for aggregation, standardization and analysis of patient clinical data, next generation sequencing (NGS) and other molecular data across public data sources, Sanofi clinical trials and Sanofi hospital partners.
NextBio's unique data integration platform, user interface and real-time Big Data analytics will allow Sanofi biologists and clinicians to tap into a vast, growing collection of patient data as it becomes available, as a key enabling technology for translational and clinical research.
"Sanofi has long used NextBio as an important component of the company's preclinical research programs," said Saeid Akhtari, President and Chief Executive Officer of NextBio.
Akhtari continued, "The new translational medicine partnership with NextBio, with its Big Data Genomics capabilities, will enable Sanofi to implement patient-centered approaches across all stages of translational and clinical research in several major therapeutic areas, including oncology and diabetes."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE